We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+13.93%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$494M
AUM Growth
+$45M
Cap. Flow
+$16.8M
Cap. Flow %
3.4%
Top 10 Hldgs %
73.47%
Holding
50
New
5
Increased
15
Reduced
12
Closed
9

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$21.3M
2
CDXS icon
Codexis
CDXS
+$7.27M
3
LRMR icon
Larimar Therapeutics
LRMR
+$5.08M
4
IRON icon
Disc Medicine
IRON
+$4.76M
5
VIGL
Vigil Neuroscience
VIGL
+$4.48M

Top Sells

Rank Stock Value
1
DNA icon
Ginkgo Bioworks
DNA
+$5.38M
2
PVLA
Palvella Therapeutics
PVLA
+$4.82M
3
ANAB icon
AnaptysBio
ANAB
+$4.66M
4
SLRN
ACELYRIN
SLRN
+$3.99M
5
TARA icon
Protara Therapeutics
TARA
+$3.02M

Sector Composition

Rank Sector Weight
1 Healthcare 97.87%
2 Miscellaneous 2.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRGX
26
DELISTED
CARGO Therapeutics
CRGX
$2.75M 0.56%
666,503
– –
MBX
27
MBX Biosciences
MBX
$3.03B
$2.73M 0.55%
239,319
-10,681
-4% -$109K
ZYME icon
28
Zymeworks
ZYME
$2.02B
$2.64M 0.53%
210,000
+35,000
+20% +$417K
TARA icon
29
Protara Therapeutics
TARA
$226M
$2.59M 0.52%
855,000
-875,000
-51% -$3.02M
ALMS
30
Alumis Inc
ALMS
$2.9B
$2.33M 0.47%
+775,000
New +$3.66M
ZNTL icon
31
Zentalis Pharmaceuticals
ZNTL
$360M
$2.23M 0.45%
1,924,300
-60,700
-3% -$80.1K
TRVI icon
32
Trevi Therapeutics
TRVI
$2.39B
$2.13M 0.43%
390,000
-405,000
-51% -$2.52M
RCEL icon
33
Avita Medical
RCEL
$320M
$2.06M 0.42%
389,519
-50,481
-11% -$367K
IRD
34
Opus Genetics
IRD
$307M
$1.15M 0.23%
1,220,000
+45,000
+4% +$41.7K
DERM icon
35
Journey Medical
DERM
$211M
$682K 0.14%
95,000
+25,677
+37% +$177K
ELEV
36
DELISTED
Elevation Oncology
ELEV
$529K 0.11%
+1,442,061
New +$481K
IBIO icon
37
iBio
IBIO
$67.6M
$285K 0.06%
375,000
– –
PEPG icon
38
PepGen
PEPG
$213M
$266K 0.05%
240,000
-180,000
-43% -$255K
ADGM
39
Adagio Medical Holdings
ADGM
$11.3M
$144K 0.03%
110,571
– –
ANAB icon
40
AnaptysBio
ANAB
$1.67B
– –
-250,933
Closed -$4.66M
BDSX icon
41
Biodesix
BDSX
$283M
– –
-161,250
Closed -$2.02M
KNSA icon
42
Kiniksa Pharmaceuticals
KNSA
$6.09B
– –
-62,501
Closed -$1.39M
NRIX icon
43
Nurix Therapeutics
NRIX
$2.72B
– –
-115,000
Closed -$1.37M
OPTN
44
DELISTED
OptiNose
OPTN
– –
-193,039
Closed -$1.77M
SGMO
45
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-1,055,000
Closed -$692K
SLRN
46
DELISTED
ACELYRIN
SLRN
– –
-1,615,000
Closed -$3.99M
VTYX
47
DELISTED
Ventyx Biosciences
VTYX
– –
-190,000
Closed -$219K
PVLA
48
Palvella Therapeutics
PVLA
$2.16B
– –
-172,357
Closed -$4.82M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2025 Portfolio in Review

As of Q2 2025, Opaleye Management held 50 positions worth $494M, up 10% from $449M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Opaleye Management deployed $16.8M of net new capital in Q2 2025, opening 5 new positions and adding to 15 existing holdings. Its largest new stake was Sarepta Therapeutics: 500,000 shares worth $8.55M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ginkgo Bioworks, an estimated $5.38M trimmed.

  • Opaleye Management's largest Q2 2025 buy was Sarepta Therapeutics: 500,000 shares worth $8.55M.
  • Opaleye Management added most to Codexis in Q2 2025, an estimated $7.27M increase.
  • Opaleye Management's biggest Q2 2025 reduction was Ginkgo Bioworks, cutting an estimated $5.38M.
  • Opaleye Management fully exited Palvella Therapeutics in Q2 2025, selling an estimated $4.82M.
  • Opaleye Management's ten largest holdings make up 73% of its $494M portfolio in Q2 2025.
  • Opaleye Management opened 5 new positions and closed 9 in Q2 2025.
  • Opaleye Management's portfolio value rose 10% quarter-over-quarter to $494M.

Based on Opaleye Management's 13F filing for Q2 2025, filed 14 Aug 2025.